# OnCo record diagnostics-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/diagnostics-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "diagnostics-roadmap" ;
  schema:name "Diagnostics roadmap: stains → gene panels → blood tests that decide treatment"@en ;
  schema:description "Cancer diagnosis moved from what a tumour looks like under a microscope to what is driving it, and now to reading it from a blood sample. The next step is tests that tell the doctor what to do, not only what is there."@en ;
  schema:url <https://onco.cc/roadmaps/diagnostics-roadmap/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2200075> ;
  onco:related <https://onco.cc/drugs/signatera/>, <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/oncotype-dx/>, <https://onco.cc/drugs/her2-testing-assays/>, <https://onco.cc/drugs/cobas-egfr-mutation-test/>, <https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/>, <https://onco.cc/drugs/guardant-reveal/>, <https://onco.cc/drugs/radar-mrd/>, <https://onco.cc/drugs/artera-ai-prostate/>, <https://onco.cc/drugs/artera-ai-breast/>, <https://onco.cc/terms/fda-ldt-rule/>, <https://onco.cc/ideas/idea-bio2-national-mrd-platform/>, <https://onco.cc/ideas/idea-bio2-mrd-coverage-with-evidence/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-crc/>, <https://onco.cc/ideas/idea-tr2-ctdna-mrd-qualification/>, <https://onco.cc/ideas/idea-tr2-biomarker-study-registry/>, <https://onco.cc/ideas/idea-tr2-marker-stratified-default/>, <https://onco.cc/ideas/idea-moon-universal-sequencing-learning-system/>, <https://onco.cc/roadmaps/early-detection-roadmap/>, <https://onco.cc/roadmaps/ai-oncology-clinic/>, <https://onco.cc/roadmaps/trial-modernisation-roadmap/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/single-cell-spatial/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/pathology-foundation-model/>, <https://onco.cc/technologies/msi-mmr-testing/>, <https://onco.cc/technologies/tmb-testing/>, <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/proteomics/>, <https://onco.cc/technologies/long-read-sequencing/>, <https://onco.cc/technologies/spatial-omics-guided-therapy/>, <https://onco.cc/technologies/continuous-ctdna-monitoring/>, <https://onco.cc/technologies/fragmentomics/>, <https://onco.cc/technologies/variant-knowledgebases/>, <https://onco.cc/technologies/reference-laboratories/> ;
  onco:trials <https://onco.cc/trials/tailorx/>, <https://onco.cc/trials/rxponder/>, <https://onco.cc/trials/dynamic/>, <https://onco.cc/trials/serena-6/>, <https://onco.cc/trials/imvigor011/>, <https://onco.cc/trials/circulate-japan/>, <https://onco.cc/trials/insight-gist/>, <https://onco.cc/trials/masai/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-data-silos/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/> .